AIM2 and bladder transitional cell carcinoma: These observations elucidate the role of AIM2 inflammasome activation in mitigating cancer progression in BLCA cells and propose that AIM2 inflammasome activation could be leveraged in developing immunotherapeutic strategies for BLCA.